LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that management has commenced preliminary due diligence and strategic planning for the company’s planned expansion into Colombia. The announcement was made on July 6, 2026, and signals the company’s intent to broaden its footprint in Latin America.
The initial phase of the expansion includes evaluating corporate, regulatory, legal, operational, and commercial requirements for establishing a Colombian operating subsidiary. This subsidiary would support the future deployment of LataMed’s digital healthcare platform in the Colombian market. Management believes Colombia represents an attractive long-term market as part of its broader Latin American expansion strategy.
The ongoing review process is expected to assess corporate formation, regulatory compliance, healthcare technology implementation, strategic partnerships, local operational infrastructure, and other market entry considerations. The evaluation aims to build upon LataMed’s growing healthcare ecosystem by identifying opportunities to expand access to telehealth infrastructure, healthcare coordination technologies, digital healthcare services, insurance accessibility initiatives, pharmacy integration opportunities, payment accessibility solutions, and artificial intelligence-driven healthcare technologies across additional Latin American markets.
Management highlighted that the continued expansion of digital healthcare infrastructure throughout Latin America presents significant opportunities to improve healthcare accessibility, strengthen patient engagement, and support technology-enabled healthcare delivery in underserved and developing markets. The company’s strategic focus is on building an integrated digital healthcare ecosystem for the region.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “Colombia represents an important strategic opportunity as we continue executing our long-term vision of building an integrated digital healthcare ecosystem across Latin America. While we remain in the early stages of evaluating market entry requirements, we believe it is important to establish the proper legal, operational, and strategic foundation before expanding into new jurisdictions. We are encouraged by the opportunities we see in Colombia and look forward to providing updates as the evaluation process progresses.”
The company emphasized that the Colombia expansion initiative remains in the preliminary planning and due diligence stage. Management intends to complete the required corporate, regulatory, and operational review before proceeding with the establishment of a Colombian subsidiary. Further updates are expected as material developments occur.
For additional information, visit LataMed AI’s website or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
This expansion could impact the healthcare landscape in Colombia by potentially increasing access to telehealth and AI-driven technologies, particularly in underserved areas. The move also reflects LataMed’s commitment to addressing healthcare accessibility challenges in emerging markets, which may influence industry trends toward digital health adoption in Latin America.
